PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
FAT vs. FGEN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between FAT and FGEN is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

FAT vs. FGEN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in FAT Brands Inc. (FAT) and FibroGen, Inc. (FGEN). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
7.78%
-42.71%
FAT
FGEN

Key characteristics

Sharpe Ratio

FAT:

-0.14

FGEN:

-0.13

Sortino Ratio

FAT:

0.16

FGEN:

0.92

Omega Ratio

FAT:

1.03

FGEN:

1.12

Calmar Ratio

FAT:

-0.12

FGEN:

-0.21

Martin Ratio

FAT:

-0.19

FGEN:

-0.30

Ulcer Index

FAT:

34.72%

FGEN:

67.41%

Daily Std Dev

FAT:

49.64%

FGEN:

151.51%

Max Drawdown

FAT:

-81.65%

FGEN:

-99.56%

Current Drawdown

FAT:

-48.56%

FGEN:

-99.11%

Fundamentals

Market Cap

FAT:

$89.74M

FGEN:

$60.35M

EPS

FAT:

-$9.22

FGEN:

-$1.33

Total Revenue (TTM)

FAT:

$447.37M

FGEN:

$152.88M

Gross Profit (TTM)

FAT:

$120.95M

FGEN:

$116.65M

EBITDA (TTM)

FAT:

$17.89M

FGEN:

-$54.59M

Returns By Period

In the year-to-date period, FAT achieves a 0.64% return, which is significantly lower than FGEN's 13.11% return.


FAT

YTD

0.64%

1M

-2.72%

6M

7.98%

1Y

-7.47%

5Y*

30.14%

10Y*

N/A

FGEN

YTD

13.11%

1M

84.22%

6M

-44.03%

1Y

-21.46%

5Y*

-57.87%

10Y*

-33.39%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

FAT vs. FGEN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

FAT
The Risk-Adjusted Performance Rank of FAT is 4141
Overall Rank
The Sharpe Ratio Rank of FAT is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of FAT is 3939
Sortino Ratio Rank
The Omega Ratio Rank of FAT is 4040
Omega Ratio Rank
The Calmar Ratio Rank of FAT is 4141
Calmar Ratio Rank
The Martin Ratio Rank of FAT is 4444
Martin Ratio Rank

FGEN
The Risk-Adjusted Performance Rank of FGEN is 4848
Overall Rank
The Sharpe Ratio Rank of FGEN is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of FGEN is 6060
Sortino Ratio Rank
The Omega Ratio Rank of FGEN is 6060
Omega Ratio Rank
The Calmar Ratio Rank of FGEN is 3636
Calmar Ratio Rank
The Martin Ratio Rank of FGEN is 4242
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

FAT vs. FGEN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for FAT Brands Inc. (FAT) and FibroGen, Inc. (FGEN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for FAT, currently valued at -0.14, compared to the broader market-2.000.002.00-0.14-0.13
The chart of Sortino ratio for FAT, currently valued at 0.16, compared to the broader market-4.00-2.000.002.004.000.160.92
The chart of Omega ratio for FAT, currently valued at 1.03, compared to the broader market0.501.001.502.001.031.12
The chart of Calmar ratio for FAT, currently valued at -0.12, compared to the broader market0.002.004.006.00-0.12-0.21
The chart of Martin ratio for FAT, currently valued at -0.19, compared to the broader market-30.00-20.00-10.000.0010.0020.00-0.19-0.30
FAT
FGEN

The current FAT Sharpe Ratio is -0.14, which is comparable to the FGEN Sharpe Ratio of -0.13. The chart below compares the historical Sharpe Ratios of FAT and FGEN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.60-0.40-0.200.000.20AugustSeptemberOctoberNovemberDecember2025
-0.14
-0.13
FAT
FGEN

Dividends

FAT vs. FGEN - Dividend Comparison

FAT's dividend yield for the trailing twelve months is around 10.46%, while FGEN has not paid dividends to shareholders.


TTM2024202320222021202020192018
FAT
FAT Brands Inc.
10.46%10.53%9.24%10.92%4.91%0.00%6.37%18.88%
FGEN
FibroGen, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

FAT vs. FGEN - Drawdown Comparison

The maximum FAT drawdown since its inception was -81.65%, smaller than the maximum FGEN drawdown of -99.56%. Use the drawdown chart below to compare losses from any high point for FAT and FGEN. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%AugustSeptemberOctoberNovemberDecember2025
-48.56%
-99.11%
FAT
FGEN

Volatility

FAT vs. FGEN - Volatility Comparison

The current volatility for FAT Brands Inc. (FAT) is 5.24%, while FibroGen, Inc. (FGEN) has a volatility of 37.48%. This indicates that FAT experiences smaller price fluctuations and is considered to be less risky than FGEN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%AugustSeptemberOctoberNovemberDecember2025
5.24%
37.48%
FAT
FGEN

Financials

FAT vs. FGEN - Financials Comparison

This section allows you to compare key financial metrics between FAT Brands Inc. and FibroGen, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab